The JV Co. has enabled Cipla to establish a front-end participation in Morocco's pharmaceutical market.

Upon completion of acquisition, Cipla EU will hold 79.16% stake in the JV Co., and balance 20.84% stake will be held by Cooper Pharma. 

Cipla Limited stated that its wholly-owned UK arm, Cipla (EU) Limited, has agreed to acquire an additional 19.16% stake in Cipla Maroc SA, a joint venture and subsidiary of Cipla EU in Morocco.

The JV Co. has enabled Cipla to establish a front-end participation in Morocco's pharmaceutical market, serving as the launch vehicle for Cipla's portfolio while leveraging partners' commercial strengths.

Upon completion of acquisition, Cipla EU will hold 79.16% stake in the JV Co., and balance 20.84% stake will be held by Cooper Pharma.